Immunotherapy for Anal Cancer

Immunotherapy is the use of medicines to stimulate a person’s own immune system to recognize and destroy cancer cells more effectively. 

Immune checkpoint inhibitors

An important part of your immune system is its ability to keep itself from attacking normal cells in the body. To do this, it uses “checkpoints” or proteins on immune cells that need to be turned on (or off) to start an immune response. Cancer cells sometimes use these checkpoints to avoid being attacked by the immune system. But drugs that target these checkpoints can be used to treat some people with anal cancer.

PD-1, a protein on certain immune cells (called T cells) normally helps keep these cells from attacking other cells in the body. By blocking PD-1, these immunotherapy drugs boost the immune response against cancer cells.

  • Nivolumab (Opdivo)
  • Pembrolizumab (Keytruda)
  • Retifanlimab (Zynyz)
  • Cemiplimab (Libtayo)
  • Dostarlimab (Jemperli)
  • Tislelizumab (Tevimbra)
  • Toripalimab (Loqtorzi)

These drugs can be used in people with anal cancer that has spread and worsened after they received at least one type of chemotherapy. Immunotherapy can shrink some tumors or slow their growth.

Retifanlimab can be given with chemo as an initial treatment for patients with anal cancer that has spread . It can also be given alone to certain patients.

These immunotherapy drugs can be given as an intravenous (IV) infusion every 2 to 6 weeks.

Possible side effects of checkpoint inhibitors

Side effects of these drugs can include fatigue, cough, nausea, itching, skin rash, loss of appetite, constipation, joint pain, and diarrhea.

Other, more serious side effects occur less often.

Infusion reactions: Some people have an infusion reaction while getting these drugs. This is similar to an allergic reaction, and can include fever, chills, flushing of the face, rash, itchy skin, feeling dizzy, wheezing, and trouble breathing. It’s important to tell your doctor or nurse right away if you have any of these symptoms while getting these drugs.

Autoimmune reactions: Immunotherapy drugs work by removing one of the defenses of the immune system. Sometimes the immune system starts attacking other parts of the body, causing serious or even life-threatening problems in the lungs, intestines, liver, hormone-making glands, kidneys, or other organs.

Report any new side effects to your health care team as soon as possible. If you have serious side effects, your treatment might be stopped and you might be given high doses of corticosteroids to suppress your immune system.

More information about immunotherapy

To learn more about how drugs that work on the immune system are used to treat cancer, see Cancer Immunotherapy.

To learn about some of the side effects listed here and how to manage them, see Managing Cancer-related Side Effects.

side by side logos for American Cancer Society and American Society of Clinical Oncology

Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).

André T, Berton D, Curigliano G, et al. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors. JAMA 2023;6:e2341165.

Li J, Xu Y, Zang A, et al. Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors. Chin J Cancer Res 2024;36:257-269.

Migden MR,Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020;21:294-305.

Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicenter, single-arm, phase 2 study. Lancet Oncol 2017;18:446-453.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma. V.4.2025. Accessed at www.nccn.org/professionals/physician_gls/pdf/anal.pdf on August 20, 2025.

Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 2017;28:1036-1041.

Pang K, Yang Y, Tian D, et al. Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial). BMJ Open 2023;13:e069499

Rao S, Anandappa G, Capdevila J, et al. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open 2022;7:100529.

Rao S, Samalin-Scalzi E, Evesque L, et al. POD1UM-303/InterAACT 2: Phase 3 study of retifanlimab with carboplatin-paclitaxel in patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy [abstract]. Ann Oncol 2024;35:S1217.

Xia F, Wang Y, Wang H, et al. Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH). J Clin Oncol 2024;42:3308-3318.

Yang Z, Zhang X, Zhang J, et al. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial). BMC Cancer 2022;22:462.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Last Revised: November 20, 2025

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.